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Abstract
Purpose: This study explored the perspectives of intended parents regarding genetic
carrier screening of a gamete donor. The main goal of this study was to determine how
much genetic carrier screening information a recipient would prefer to receive about
potential donors. The study also aimed to identify factors that potentially influence a
recipient’s choice of donor based on genetic screening results. Methods: An online
questionnaire was developed to assess intended parents’ preferences regarding expanded
carrier screening (ECS) of their donors. Participants were recruited from various online
support groups and were eligible if they had previously utilized or were currently
utilizing donor gametes. A total of 58 usable responses were collected and reflect insight
into the perspectives of intended parents regarding which factors associated with genetic
carrier screening influence their choice of donor. The questionnaire consisted of
demographic questions, general questions about carrier screening, a genetics knowledge
quiz, and questions about hypothetical scenarios in which a donor was a carrier for one of
four distinct conditions: hemochromatosis, Usher syndrome, Bardet-Biedl syndrome, and
GRACILE syndrome. Results: The majority of women (91.4%, 53/58) opted for ECS of
their potential gamete donor, preferred over traditional ethnicity- or family history-based
screening. Participants were comfortable proceeding with a donor with the knowledge
that he/she was a carrier for a mild genetic condition (hemochromatosis, 83.3%). Fewer
respondents were comfortable proceeding with a donor who was a carrier for a more
severe condition (Usher, 37.0%; BBS, 39.1%; GRACILE, 39.1%). Conclusion: Intended
iv

parents prefer ECS for their donors over traditional ethnicity- or family history-based
screening. Participants were uncomfortable with a donor who is a carrier for severe, lifelimiting conditions, regardless of statistical risk. Expanded carrier screening is desired
and could be beneficial for use in gamete donation; however, given the overall discomfort
with identification of positive carrier status, ECS would significantly alter clinical
decision making in these settings. Increased genetic education of recipients on the
implications of ECS carrier results is indicated, and access to genetic counseling services
may be indicated for optimal implementation.
Keywords: gamete donation, expanded carrier screening, recipient perspectives.
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Chapter 1: Background
1.1 Impaired fertility and assisted reproductive technology (ART)
Impaired fertility is the reduced ability to achieve or maintain pregnancy, while
infertility is the inability to conceive altogether. According to the most recent data
published by the Center for Disease Control and Prevention (CDC, 2015), approximately
6.7 million women and 1.5 million women aged 15-44 are affected by impaired fertility
and infertility, respectively. Fertility problems can arise through male or female factors,
or have an unknown etiology. Depending on the cause, there are several management
options for couples struggling with fertility issues, and the CDC has estimated that 7.4
million women aged 15-44 have ever utilized infertility services. In addition to women
with impaired fertility or infertility, same-sex couples and single women also commonly
seek fertility care. Fertility treatment options for anyone seeking fertility care include the
use of ovulation predictor kits, oral and injectable ovulation-inducing agents, intrauterine
insemination, and assisted reproductive technologies (Gunn & Bates, 2016).
Assisted reproductive technology (ART) is defined as any fertility treatment that
utilizes eggs or embryos handled in a laboratory. Although ART includes in vitro
fertilization (IVF), gamete intrafallopian transfer, and zygote intrafallopian transfer, IVF
constitutes 99% of all ART procedures performed. In a typical IVF cycle, a woman’s
eggs are stimulated with medication and surgically retrieved. Once retrieved, the eggs are
combined with sperm to facilitate fertilization. Viable embryos are either selected for
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transfer into the uterus or cryopreserved for use at a later time. By definition, ART does
not include any procedures in which only sperm are handled (i.e. intrauterine
insemination) or treatments in which women take medication to stimulate ovulation or
egg production but do not have their eggs retrieved (Sunderam et al., 2015).
Assisted reproductive technology and other fertility treatments facilitate the use of
donor gametes for couples unable to conceive using their own eggs or sperm. Indications
for therapeutic donor insemination, or the use of donor sperm, include significant sperm
or seminal fluid abnormalities (e.g. azoospermia, oligospermia), ejaculatory dysfunction,
or other male factor infertility in the male partner, male partner carrier status of a genetic
condition, or females without a male partner. Utilization of donor oocytes may be
indicated when the woman is of advanced maternal age, has premature ovarian
insufficiency or diminished ovarian reserve, is a carrier of a genetic condition, or had
poor oocyte/embryo quality in previous ART cycles (ASRM, 2013). The use of donor
gametes to facilitate family formation is now well established.
1.2 Current guidelines, recommendations, and concerns regarding gamete donation
Gamete donation is regulated by the Food and Drug Administration (FDA)
because of its classification within donation of human cells, tissues, and cellular and
tissue-based products (HCT/Ps). As such, the practice must follow clear guidelines for
the screening of donors (ASRM, 2013). The American Society for Reproductive
Medicine (ASRM) has issued their own recommendations for the evaluation of sperm,
oocyte, and embryo donors, which includes the minimum federal requirements set by the
FDA. The latest recommendations from the ASRM, which also recommend testing of
recipients, include semen testing for males, thorough medical history evaluation, physical
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examination, psychological examination, laboratory testing, including infectious disease
and hormone testing, and genetic evaluation. While the FDA does not require genetic
evaluation of donor HCT/Ps, it is recommended by the ASRM that all donors undergo
genetic screening (ASRM, 2013).
Specifically, the ASRM recommends testing all potential donors for cystic
fibrosis carrier status. While chromosomal analyses are not required for all donors, other
genetic carrier screening should be implemented as indicated by the donor’s ethnic
background and medical and family history. While it is not required, consideration for
fragile X carrier screening should be considered for egg donors (ASRM, 2013). Genetic
carrier screening based on ethnic background should follow current available
recommendations by the American College of Obstetrics and Gynecology (ACOG) and
American College of Medical Genetics and Genomics (ACMG). The ASRM adds that,
because over time, tests improve and new tests become available, cryopreserved
specimens may not meet current standards at the time of use. In these instances, every
effort should be made to re-contact and rescreen the donor to meet current guidelines.
When obtaining personal and family history information, careful attention should
be given to look for heritable diseases. According to the current guidelines, the donor
should not have any major Mendelian disorder, major malformations of complex causes,
significant familial disease with major genetic components, or a known karyotypic
abnormality that may result in chromosomally unbalanced gametes. If the family history
reveals a disorder for which carrier screening is available, the donor should be referred
for genetic counseling (ASRM, 2013).
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Individual gamete donation programs have different policies regarding screening
for heritable disorders. A 2013 study on the genetic screening practices of thirteen sperm
banks in the United States revealed that while all facilities followed the genetic screening
guidelines of at least one professional organization, there were many discrepancies as to
which organization’s guidelines they followed. Some directly followed the guidelines of
relevant organizations such as ACMG or ACOG; however, many facilities frequently
followed the guidelines of tissue banking and reproductive organizations such as the
ASRM or the American Association of Tissue Banks (AATB). Regardless, all facilities
stated that they would perform additional testing if requested by the recipients (Isley &
Callum). Because of the lack of consistent guidelines from professional organizations,
there is great variation in genetic screening protocols across programs in the United
States. This variation can lead to insufficient genetic screening of donors, which may in
turn lead to avoidable high-risk pregnancies. Gamete donation programs may benefit
from consensus guidelines for achieving consistency in the genetic screening of donors.
Frith, Sawyer, and Kramer (2012) called for greater uniformity to ensure that recipients
are well informed of their options and are better able to choose between programs and
donors.
There are other limitations to the screening of donors. Because the medical and
genetic status of a person affects donor eligibility, it is essential that donors are truthful of
their personal medical, family, and social histories. The responsibility of protecting the
health of the donor-conceived offspring falls on the gamete donation programs, so it is
imperative that qualified clinicians evaluate the donor’s personal medical, family, and
social histories (Ethics Committee of the ASRM, 2014). While the ASRM (2013) states
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that a family history review is best performed by a genetic counselor, not all programs
follow this guideline. The aforementioned study revealed that while all facilities obtain a
three-generation family history from their prospective donors, the review of family
history was performed by different professionals at each clinic, including nurse
practitioners, reproductive endocrinologists, medical geneticists, genetic counselors, and
medical directors (Isley & Callum, 2013). This variation may also contribute to some of
the variation of screening practices in gamete donation programs.
1.3 Perspectives of patients utilizing donor gametes
While research is limited, there have been several studies exploring the
perspectives of the recipients – the intended parents – of donor gametes. The factors that
influence the recipient’s choice of donor are relatively well characterized. A few studies
found that non-genetic parents felt it important to them to choose a donor that would
create offspring who were “passable” as their own genetic children (Frith, Sawyer, &
Kramer, 2012; Rubin et al., 2015). Specifically, a 2012 study found that sperm recipients
matched donors by ethnicity (83%), skin coloring (70%), and interests (53%). In the same
study, matching for height and build were also found to be important to intended parents
(Frith, Sawyer, & Kramer, 2012). Physical health was found to be equally, if not more,
important to physical characteristics in all studies (Frith, Sawyer, & Kramer, 2012;
Sawyer et al., 2013; Hershberger, 2004; Rubin et al., 2015). A 2013 study found that the
majority of parents identified the donor’s personal and family health among the most
important attributes, and about half of the participants disclosed that they would reject
donors who fit their criteria but had health issues in their personal and family histories
(Sawyer et al.). The 2012 study participants were concerned about the health of the
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donors and explicitly stated that donor medical screening practices were very important
to them (Frith, Sawyer, & Kramer).
One area of research that is lacking is the recipients’ preferences regarding the
genetic screening of donors. A study from 2008 revealed that couples had varying
preferences when it came to genetic screening of their donor. Many couples chose to
decline recommended screening tests. It was also clear from this study that the outcome
of screening may affect a couple’s decision to continue with that particular donor (Baker,
Rone, & Adamson, 2008). When prompted, another study found that 67% of recipients
agreed that all sperm banks should be required to perform comprehensive genetic
screening on their donors, and 84% would pay more for donors who had undergone more
comprehensive screening (Sawyer et al., 2013). While not specific to genetic screening,
one study found that more specific information placed more focus on donor imperfections
and added to the burden of choosing (Rubin et al., 2015). Additional research into
recipient preferences may be incorporated into the development of new donor screening
guidelines.
1.4 Current guidelines, recommendations, and concerns regarding genetic carrier
screening
Screening for Mendelian disorders originated more than 50 years ago and is
widely implemented in obstetric care. It is able to achieve two different outcomes:
screening for a disease in an individual (the goal of newborn screening), and screening
for carrier status in an unaffected individual (the goal of carrier screening). While
newborn screening (NBS) is a required practice to screen newborns for Mendelian
disorders, carrier screening may be implemented based on ethnicity, family history, or
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personal request (Rose & Wick, 2015). Genetic carrier screening is the identification of
potential inherited disorders in unaffected patients without a previous history of disease,
which may later affect themselves or their offspring (Gil-Arribas, Herrer, & Serna, 2016;
Edwards et al., 2015). Carrier screening is generally performed during the prenatal or
preconception periods. If performed during pregnancy, carrier screening of the parents
during pregnancy can determine need for genetic testing of the embryo or fetus, which
can provide obstetric options or information for neonatal care. Preconception carrier
screening provides information for reproductive risk and prevention strategies such as
preimplantation genetic diagnosis (PGD) or the use of donor gametes.
Screening panels most commonly include variants of genes associated with
autosomal recessive (AR) conditions, which require two mutated copies of a gene at a
particular locus in order to express that particular trait or disorder. Affected individuals
typically inherit two mutated copies of a gene, one from each of their parents (Rose &
Wick, 2015). Most of the conditions included in carrier screening panels significantly
affect an individual’s quality of life, either cognitively or physically, and have an early
onset (i.e. fetal, neonatal, early childhood) with well-defined phenotypes (Edwards et al.,
2015).
Carrier screening can identify individuals who are at risk of passing on mutated
genes to their offspring, which is particularly important for couples considering
pregnancy. If both partners are carriers of a specific gene mutation for a particular AR
condition, each conception would have a 25% chance of inheriting both mutated copies
of the gene and being affected with the condition (Rose & Wick, 2015). Carrier screening
for couples can occur simultaneously or sequentially. If a couple opts for simultaneous
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screening, both individuals are screened at the same time for the same set of disorders.
When performed sequentially, one person is screened first; if he or she is found to be a
carrier of a mutation, screening for the other partner would be recommended. If the first
partner is not a carrier of any mutations, screening of the second partner would be
unnecessary, as the child would not be at increased risk of being affected with the AR
conditions tested. Sequential screening is beneficial because it may eliminate the
unnecessary need to test both partners; however, it may delay an eventual diagnosis and
limit the available options (Rose & Wick, 2015).
While most carrier screening panels focus on AR conditions, individuals can also
be tested for X-linked (XL) conditions. X-linked conditions occur from a mutation of a
gene on the X chromosome. Female carriers of a mutation for an XL condition may or
may not exhibit the phenotype, depending on the distribution of X inactivation. Female
carriers have a 50% chance of passing their mutation on to their children, and males
inheriting an XL mutation have a high likelihood of being affected. Males with XL
mutations (who are typically symptomatic of the associated condition), on the other hand,
will transmit their mutation to all of their daughters. Their sons, however, will not be at
risk of inheriting the mutation (Rose & Wick, 2015).
Genetic carrier screening for some conditions, such as cystic fibrosis and spinal
muscular atrophy, are routinely offered to couples before or during pregnancy (Rose &
Wick, 2015). Certain mutations for several AR conditions have been found to be more
common in individuals of Ashkenazi Jewish (AJ) descent, and screening guidelines have
been established for these disorders. The ACMG currently recommends carrier screening
in the AJ population for the following AR conditions: cystic fibrosis, Tay-Sachs disease,
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Canavan disease, familial dysautonomia, Fanconi anemia group C, Niemann-Pick disease
type A, mucolipidosis IV, Bloom syndrome, and Gaucher disease (2008). The ACOG
Committee on Genetics recommends that all AJ individuals be offered screening for
cystic fibrosis, Tay-Sachs disease, Canavan disease, and familial dysautonomia, while
individuals should be able to inquire about the other listed AJ disorders (2009). Several
other disorders for which other ethnicities are at a higher risk also exist; therefore, genetic
carrier screening has historically been ethnicity-based. (Rose & Wick, 2015).
Genetic carrier screening based on ethnicity, while helpful, is problematic for
several reasons. Mixed ethnicities, unknown ancestry, adoption, unclear definitions for
race and ethnicity, and the fact that genetic conditions are not confined to certain ethnic
groups all pose problems in determining the best screening to offer individuals (Rose &
Wick, 2015; Nazareth, Lazarin, & Goldberg 2015; Gil-Arribas, Herrer, & Serna, 2016;
Edwards et al., 2015; Lazarin et al., 2013). Furthermore, conflicting or otherwise
inconsistent guidelines from professional organizations and relatively limited guidelines
leads to inconsistencies across practices (Nazareth, Lazarin, & Goldberg, 2015). Aided
by an increasingly multi-ethnic population and the idea that NBS is not ethnicity-based,
there has been a trend away from ethnicity-based carrier screening towards a more panethnic approach (Nazareth, Lazarin, & Goldberg, 2015; Edwards et al., 2015; Lazarin &
Hague, 2015; Henneman et al., 2016). A joint position statement by the National Society
of Genetic Counselors (NSGC), ACMG, ACOG, Perinatal Quality Foundation, and the
Society for Maternal-Fetal Medicine has laid out points to consider for carrier screening
for women of reproductive age before conception, and suggested carrier screening of
gamete donors be considered as part of all screening programs (Edwards et al., 2015).
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1.5 Current guidelines, recommendations, and concerns regarding expanded carrier
screening
The incorporation of next-generation sequencing technologies has made carrier
screening both more available and more cost effective (Rose & Wick, 2015; Lazarin &
Hague, 2015; Lazarin et al., 2014). This allows for the detection of increasingly larger
numbers of mutations at one time, which allow for more expanded panels of conditions.
Clinically introduced in 2009, expanded carrier screening (ECS) panels can test for more
than 100 genetic conditions at one time (Edwards et al., 2015). Expanded carrier screens
typically include conditions that are included on traditional carrier screening panels, with
the addition of other rare AR and XL conditions. These conditions may have significant
variation in their presentation or more undefined phenotypes. While conditions on
expanded panels vary in severity, many are associated with cognitive impairment,
decreased life expectancy, and need for medical or surgical intervention (Edwards et al.,
2015; Lazarin & Hague, 2015). Taking into account the fact that Mendelian diseases
account for about 20% of both infant mortality and infant hospitalizations, many find it
reasonable to consider an expanded disease list for all populations (Lazarin & Hague,
2015; Henneman et al., 2016).
Conditions included on ECS vary between laboratories and clinical practices.
While the list of conditions is not regulated, professional organizations have set forth
guidelines for which conditions should be considered to be included on panels.
Conditions being screened for should be a health problem that encompasses either
cognitive disability, need for surgical or medical intervention, or an affected quality of
life, and should include conditions for which prenatal diagnosis may result in
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intervention, delivery management, or prenatal education, or a combination. Genes and
variants for these conditions should have a well-understood phenotypic relationship based
on strong evidence that is not limited solely to case reports (Edwards et al., 2015; Grody
et al., 2013). Testing for conditions characterized by incomplete penetrance or variable
expressivity, or conditions associated with mild phenotypes, should be made optional for
individuals undergoing expanded carrier screening. Additionally, when adult-onset
disorders are included in panels, individuals must be well informed about the chance of
finding out about a potentially unexpected health risk before providing consent (Grody et
al., 2013).
Recently, a taxonomy has been developed to group disorders into categories based
on their impact on affected offspring: significantly shortened lifespan, serious medical
problems, mild medical problems, unpredictable medical outcomes, and adult-onset
conditions. This taxonomy has potential to be used to describe groups of conditions, and
it was suggested that patients could opt out of receiving information for types of
conditions that were not important to them (Leo et al., 2016).
Benefits of ECS include better identification of at-risk pregnancies and couples
for greater availability and utilization of pregnancy management options. For potential
offspring, ECS may lead to reduction of diagnostic time and costs, earlier availability and
utilization of treatments and preventions, reduction of unnecessary treatments, and
improvement of quality of life (Kingsmore, 2012). Expanded carrier screening, when
implemented in practice, is able to identify many more at-risk couples compared with
traditional ethnicity-based carrier screening. A 2013 study of ECS for 96 conditions
identified 24% of individuals as heterozygous for at least one condition. Furthermore,
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among identified mutations, 77% were for conditions not included in ACOG screening
guidelines and 69% were for conditions not included in ACMG guidelines (Lazarin et al.,
2013). Other studies have cited carrier rates ranging from 25% to 85% (Franasiak et al.,
2016; Martin et al., 2015; Abuli, Rodriguez-Santiago, & Coroleu, 2016). These
differences can be attributed to the variation of conditions and variants screened for
among different expanded panels. In addition to identifying individuals as carriers,
Martin et al. (2015) identified 5% of couples in an infertility practice to be at high risk for
conceiving an offspring with an AR condition, and Abuli, Rodriguez-Santiago, and
Croleu (2016) identified 3% of pre-assigned donor-recipient matches to have high
reproductive risk. By identifying carriers and at-risk couples, ECS may lead to a
reduction in the number of children born with the conditions that are screened for
(Henneman et al., 2016).
Due to the identification of more at-risk couples, ECS may result in more couples
undergoing prenatal diagnosis or choosing to utilize PGD or donor gametes as a way of
managing increased reproductive risks. Gil-Arribas, Herrer, and Serna (2016) explained
that ECS provides maximum benefits in gamete donor programs, since current prevention
of genetic disorders relies on medical history and limited genetic testing. Several studies
have even suggested the implementation of donor matching programs based on carrier
screening results in order to efficiently avoid genetically high-risk pregnancies (GilArribas, Herrer, & Serna, 2016; Martin et al., 2015; Silver et al., 2016).
While there are many benefits, concerns about ECS revolve around the counseling
burden it poses. Because expanded panels screen for more disorders, a higher proportion
of individuals tested will be found to be carriers and may require counseling about their
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results (Benn et al., 2014). Other concerns include unnecessary prenatal diagnosis and
termination for mild disorders, false reassurance for those who test negative, and a false
understanding that ECS tests for “everything.” Additionally, it is unreasonable to provide
detailed descriptions of each condition being tested for prior to screening, which may
hinder informed decision-making and consent.
1.6 Attitudes toward genetic carrier screening
While ECS is not widely implemented across practices, attitudes towards ECS are
generally favorable among medical professionals. One study found that most (78%)
women’s healthcare providers would prefer to be tested for a larger number of diseases, if
costs were the same as a smaller panel (Ready et al., 2012). Similarly, 90% of genetic
counselors felt they would want to be screened for conditions beyond the ACMG and
ACOG recommendations (Lazarin et al., 2015). In general, providers had positive
attitudes towards carrier screening and believed it to be “socially responsible” behavior
(Ready et al., 2012).
A focus group of individuals who had previously undergone preconception carrier
screening revealed that patients were somewhat divided on undergoing ECS. While some
individuals desired any and all information possible to achieve a sense of control in
reproductive decision making, other hesitant individuals stated that more information
would be anxiety-provoking and would ultimately not affect their reproductive decisions
(Schneider et al., 2015). A European study found that among individuals of reproductive
age, 34% stated that they would undergo ECS while 51% remained undecided. The same
study cited prevention of and preparation for serious heritable disease as among the most
important reasons to undergo expanded carrier screening (Plantinga et al., 2016). Most
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recently, a study in the Netherlands found that among individuals in the Dutch Jewish
community, genetic carrier screening is generally perceived as favorable and having high
benefits. The same study found that slightly more than half (53.8%) of the participants
preferred pan-ethnic ECS over ethnicity-based carrier screening. Important reasons for
this preference revolved around potential stigmatization with ethnicity-based screening,
and the difficulty in determining individuals at risk in an increasingly ethnically-diverse
population (Holtkamp et al., 2016).
Among genetics professionals surveyed in a 2013 study, benefits of ECS revolved
around the prevention of heritable diseases. They also felt that patients undergoing ART
may be more interested in ECS, as couples have already undertaken the financial burden
of IVF and therefore would find additional costs (e.g. ECS or PGD) less demanding.
Additionally, participants felt that expanded screens had more financial value than
traditional carrier screens. Perceived limitations included the lack of guidelines provided
by professional organizations on the use of ECS, and the inability to fully eliminate risks
of other rare conditions for which screening was not performed. Many agreed that the
decision to recommend ECS was highly individualized and would need to consider the
specific informational needs of each individual or couple. Furthermore, it is important to
consider that as the number of conditions being screened for increases, the possibility of
finding a variant of unknown significance (VUS) increases significantly. In general,
genetics professionals felt that ECS has major limitations and is not ready for routine
reproductive care (Cho et al., 2013).
A recent study explored the attitudes of European geneticists towards ECS
(Janssens et al., 2017). All participants recognized the potential benefits of ECS,
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including the identification of at-risk couples without a preexisting risk; however, they
identified several major limitations. Many geneticists noted that ECS is unable to identify
many carriers because of rare or novel pathogenic mutations not included in ECS panels.
They felt that this residual risk would lead to undue anxiety in couples where only one
partner was found to be a carrier. Some participants anticipated a lower prevalence of AR
conditions with the implementation of ECS, which they felt could lead to perceived
eugenic undertones of carrier screening and negative implications for people with the
screened disorders (Janssens et al., 2017).
Current literature identified pretest counseling as a major limitation of ECS.
Ninety-two percent of genetic counselors surveyed stated that pretest counseling should
be required for all patients prior to having ECS (Lazarin et al., 2015), and a study of other
genetics professionals had similar findings (Cho et al., 2013). One difficulty with pretest
counseling is due to the large number of disorders on expanded screening panels. It
would be impractical for any healthcare provider to provide details of each condition,
particularly given the current shortage of genetic counselors available to have these
discussions (Benn et al., 2014; Leo et al., 2016). Only 31% of genetic counselors agreed
that pretest counseling could be administered through informational pamphlet/brochure
or video (Lazarin et al., 2015). Considering that online information about ECS is often
distributed by for-profit companies (Holton, Canary, & Wong, 2016), there is room for
additional research to identify the best practices to educate patients in a non-biased
manner to allow for an informed decision about ECS (Abuli, Rodriguez-Santiago, &
Coroleu, 2016).
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1.7 The use of expanded carrier screening in ART
Genetic carrier screening in a gamete donor population is markedly different from
carrier screening of couples. Firstly, donors provide gametes for offspring that they will
not parent. This may reduce informational need or the feelings of genetic burden that
typical genetic parents may face. Therefore, donors’ preferences regarding genetic testing
is not generally the predominant factor that determines which evaluations are performed
(Isley & Callum, 2013). Donors generally do not go to ART clinics to learn of their
genetic reproductive risks (Abuli, Rodriguez-Santiago, & Coroleu, 2016). Additionally,
all screening in donor programs would occur before conception, reducing the need for
prenatal decision making faced by many couples undergoing carrier screening during
pregnancy.
Although a potential drawback for carrier screening of donors is the psychosocial
harm of positive results for donors and their families, research shows that while carriers
scored higher in emotional and psychological impact questionnaires than non-carriers,
none of the subjects had pathologic HADS-D and STAI scores. Furthermore, ECS
seemed to be well tolerated and accepted by participants (Abuli, Rodriguez-Santiago, &
Coroleu, 2016).
Still, ECS is not a routine practice in ART or gamete donation clinics, though
several studies have explored its potential utility. A study in 2015 revealed that ECS in a
population of individuals undergoing ART identified 85% of the population to be carriers
for at least one pathogenic or likely pathogenic mutation. Furthermore, ECS was able to
identify 2% of egg donors as carriers of XL disorders. These donors were discarded from
their program, when they otherwise may not have been (Martin et al., 2015). A similar
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study identified 56% of ART patients to be carriers of mutations and 1.7% of egg donors
to be carriers of XL conditions (Abuli, Rodriguez-Santiago, & Coroleu, 2016). One study
screened previously negative sperm donors, who were initially screened only for cystic
fibrosis. After four additional carrier assessments, including an expanded panel, all
donors were found to carry at least one defined variant of a genetic condition (Silver et
al., 2016). These results suggest that the current standard of care (i.e. limited or ethnicitybased screening) is perhaps insufficient in reproductive medicine. In order to provide
accurate risk assessments, it is important to detect carriers of genetic conditions, and
screening standards should be updated to reflect the high variant carrier rates in an
increasingly multi-ethnic population.
In a recent retrospective study of individuals who had undergone ECS, Haque et
al. (2016) attempted to quantify the modeled risk of recessive conditions. Using random
pairings of individuals from within and across different ethnic backgrounds, they were
able to quantify the proportion of hypothetical fetuses who would be homozygous or
compound heterozygous for mutations known to cause disease. From a study population
of almost 350,000 individuals, it was calculated that the frequency of fetuses potentially
affected by hereditary conditions ranged from 94.5 to 392.2 per 100,000 couples,
depending on ethnicity. When compared with current genetic carrier screening practices,
this study found that ECS was able to identify more hypothetical fetuses at risk (Haque et
al., 2016). Because this study only analyzed the screening results of individuals without
infertility or a personal/family history of genetic disease, the results may potentially be
more representative of the cohort who may be selected for gamete donation, especially in
a population with diverse races and ethnicities.
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While ECS may identify more potential gamete donors as carriers of AR
conditions, the risks of other inherited disorders must not be overlooked and should be
included in patient counseling. A retrospective review of outcome reports of donorconceived offspring revealed that of the 108 semen donors where vial distribution was
restricted for suspected or confirmed heritable conditions, only 35 were due to AR
conditions. Eleven donors were restricted for suspected or confirmed autosomal dominant
(AD) conditions; however, the majority were restricted for multifactorial disorders (Isley,
et al. 2016). Expanded carrier screening may identify more individuals at risk for AR
conditions; however, it is unable to reduce the risk of most AD and multifactorial
conditions.
Relatively little is known about the intended parents’ preferences regarding ECS
of their donors. Since AR diseases require inherited mutations from both genetic parents,
a high-risk donor – one who carries a variant in the same AR condition as the other
genetic parent – for one recipient is likely to be a low-risk donor for most other recipients
(Silver et al., 2016). More information about recipients’ genetics knowledge may be
helpful in understanding the factors that influence choice of screening and/or donor. One
study showed that among patients at reproductive genetics clinics who were counseled on
ECS, only 4% and 12% in academic and private settings, respectively, accepted such
screening. Still, as ECS becomes increasingly common it may become the “standard of
care” and may be better received by the general population (Schoen et al., 2015).
1.8 Need for current study
Exploring the perspectives of intended parents about how genetic screening results
influence their choice of donor would be helpful in determining the potential utility of
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ECS in gamete donation practices. These perspectives may identify potential areas of
improvement in educating patients about genetic carrier screening results. Increased
knowledge of the implications of carrier status on future offspring may help to reduce the
unnecessary discarding of variant-positive donors. Additionally, understanding the
genetic screening preferences of parents utilizing donor gametes may lead to increased
uniformity of genetic screening practices in gamete donation programs. Consistent and
increased genetic screening practices will increase identification of at-risk conceptions
and subsequent prevention of heritable conditions.
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Chapter 2: Recipients’ Perspectives Regarding Expanded Carrier
Screening of Gamete Donors
2.1 Abstract
Purpose: This study explored the perspectives of intended parents regarding genetic
carrier screening of a gamete donor. The main goal of this study was to determine how
much genetic carrier screening information a recipient would prefer to receive about
potential donors. The study also aimed to identify factors that potentially influence a
recipient’s choice of donor based on genetic screening results. Methods: An online
questionnaire was developed to assess intended parents’ preferences regarding expanded
carrier screening (ECS) of their donors. Participants were recruited from various online
support groups and were eligible if they had previously utilized or were currently
utilizing donor gametes. A total of 58 usable responses were collected and reflect insight
into the perspectives of intended parents regarding which factors associated with genetic
carrier screening influence their choice of donor. The questionnaire consisted of
demographic questions, general questions about carrier screening, a genetics knowledge
quiz, and questions about hypothetical scenarios in which a donor was a carrier for one of
four distinct conditions: hemochromatosis, Usher syndrome, Bardet-Biedl syndrome, and
GRACILE syndrome. Results: The majority of women (91.4%, 53/58) opted for ECS of
their potential gamete donor, preferred over traditional ethnicity- or family history-based
screening. Participants were comfortable proceeding with a donor with the knowledge
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that he/she was a carrier for a mild genetic condition (hemochromatosis, 83.3%). Fewer
respondents were comfortable proceeding with a donor who was a carrier for a more
severe condition (Usher, 37.0%; BBS, 39.1%; GRACILE, 39.1%). Conclusion: Intended
parents prefer ECS for their donors over traditional ethnicity- or family history-based
screening. Participants were uncomfortable with a donor who is a carrier for severe, lifelimiting conditions, regardless of statistical risk. Expanded carrier screening is desired
and could be beneficial for use in gamete donation; however, given the overall discomfort
with identification of positive carrier status, ECS would significantly alter clinical
decision making in these settings. Increased genetic education of recipients on the
implications of ECS carrier results is indicated, and access to genetic counseling services
may be indicated for optimal implementation.
Keywords: gamete donation, expanded carrier screening, recipient perspectives.
2.2 Introduction
Couples utilizing donor gametes (egg and/or sperm) consider many factors when
selecting a donor. Many couples seek donors who will provide offspring that are
“passable” as their own biological children, and so will select donors based on ethnicity
and other factors such as eye and hair color. Aside from physical characteristics,
recipients have stated that health of the donor and donor’s family is among the most
important attributes; however, screening for physical health relies largely on donors to be
truthful about their personal and family health histories (Frith, Sawyer, & Kramer, 2012).
Additionally, the majority of babies born with an autosomal recessive (AR) condition
have no family history of the disease. Genetic carrier screening, however, can help
ameliorate some of this uncertainty by identifying donors who are at risk of passing down
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mutations for an AR condition, which may otherwise be missed by only assessing family
history.
Gamete donation is regulated by the Food and Drug Administration as human
tissue donation; to date, there are no clear guidelines for the genetic testing of gamete
donors. The American Society for Reproductive Medicine (ASRM), however, has issued
recommendations regarding the testing of donors. The ASRM recommends testing for
cystic fibrosis carrier status in all potential donors and carrier screening for other
conditions as indicated by the donor’s ethnicity and family history (ASRM, 2013). Still,
donor screening practices differ widely throughout the United States, creating variation in
the number of conditions for which donors are tested. Furthermore, an increasingly multiethnic population makes it difficult to determine who should be screened for which
conditions. Thus, consideration of a pan-ethnic expanded carrier screen for all potential
gamete donors may be warranted.
Although there is general acceptance of ECS from healthcare professionals
(Ready et al., 2012; Lazarin et al., 2015), little is known about gamete recipient
preferences regarding expanded carrier screening of their donors. Therefore, exploring
the perspectives of intended parents would be helpful in determining the potential utility
of ECS in gamete donation practices.
2.3 Materials and Methods
2.3.1 Participants. This study targeted current and past recipients of donor gametes.
Individuals were invited to participate if they were currently in the process of choosing or
utilizing gamete donors, or if they had a child conceived through the use of donor
gametes. Either the genetic or non-genetic parent of a donor-conceived child may have
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participated. No exclusion regarding method of conception (intrauterine insemination vs.
in vitro fertilization) was established; however, as this study focused on recipients’
preferences, gamete donors were excluded from this study.
Recruitment occurred through posting of an announcement (Appendix A) about
the research study, which provided a brief introduction, invitation, and link to the
questionnaire on SurveyMonkey. The announcement was posted on various online
support groups for infertility and donor conception, and included the Donor Conception
Support Group Australia website, the Southwestern Ontario Donor Conception Support
Network Canada website and Facebook group, the Single Mothers by Choice Facebook
group, the Parents Via Egg Donation website, and the Resolve national infertility
association website. Permission was obtained from representatives of each group prior to
posting of the announcement. The invitation described the study to participants, provided
the investigators’ contact information, and allowed participants to access the study.
Participants were then able to decide whether they wanted to continue with the
questionnaire.
A total of 58 respondents completed the online questionnaire. Table 2.1
summarizes demographic information. All individuals identified as females aged 29-55.
The sample population had a mean age of 40 years (SD = 6.2), with most women (63.2%)
reporting their age as being between 36 and 45 years. The majority of women were single
(81.0%), identified as Caucasian (93.1%), lived in the United States (77.6%), and had a
graduate level degree (65.5%).
2.3.2 Study Methods. Potential participants were able to view the invitation to
determine whether they were interested in and eligible for the study. Informed consent
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was considered to be provided once a patient accessed the questionnaire, which was
expected to take approximately 15 minutes to complete. Participants could withdraw
from the study at any time by not completing the questionnaire.
2.3.3 Study Measures. An original online questionnaire developed through
SurveyMonkey.com was designed with questions to identify intended parents’
preferences regarding genetic carrier screening of gamete donors, as well as characterize
factors that influence a recipient’s choice of gamete donor based on genetic carrier
screening results.
Quantitative questions were asked to assess categorical information about the
participants, such as gender, age, ethnicity, and education level of the intended parents.
Additionally, the data collected was used to provide information about the preferences of
recipients regarding genetic carrier screening, as well as donor selection based on genetic
results. Factors influencing donor selection were assessed through a series of questions
intended to assess the importance of various elements, such as comparisons of carrier
status and family history. The intended parents’ understanding of genetics concepts and
nature of genetic carrier screening was also assessed. Finally, the potential utility of a
genetic counselor in explaining the relevant concepts for recipients during the donor
selection process was assessed. The questionnaire contained multiple choice, select all
that apply, ranking, and open-ended questions.
2.3.4 Statistical Analysis. Quantitative questions from the online survey were
analyzed using descriptive statistics. The data produced was categorical. Calculation of
frequencies and percentages for these questions was completed to quantify and
summarize the preferences and factors identified. Independent t-tests were performed to
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explore differences in the way participants answered questions amongst four distinct
conditions. Qualitative analysis of open-ended responses was performed using grounded
theory methods.
2.4 Results
2.4.1 Personal history with use of donor gametes. Table 2.2 shows the participants’
personal histories with use of donor gametes. Of the study participants, 87.9% (51/58)
had previously attempted to conceive with a sperm or egg donor and 74.5% (38/51) had
achieved a live birth. At the time of the study, 18.9% (11/58) were currently seeking
sperm or egg donors. The majority of participants (82.8%) reported that single
motherhood was their main reason for using a donor.
2.4.2 Preferences for level of genetic carrier screening. Participants were given a
brief introduction to genetic carrier screening and the differences between ethnicity or
family history-based carrier screening and ECS. Twenty-one women (36.2%) reported
that they personally had carrier screening previously. When prompted to provide the
number of conditions for which they were screened, the range provided was between one
and 500 conditions. In contrast, 67.9% reported that their donor had carrier screening.
The number of conditions for which their donors were reportedly screened ranged
between five and 100 conditions.
When asked to choose between ethnicity or family-history based carrier screening
and ECS, the majority of women opted for ECS for themselves (72.4%) and their donors
(91.4%). Significantly more women had no preference when deciding between different
screening options for themselves than when they were deciding for their donors. A chisquare test for association was conducted between preference of genetic screening for self
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and genetic screening for donor. Cell frequencies were greater than five for ECS, but not
for ethnicity/family based screening or no preference. There was a statistically significant
association between preference of genetic screening for self and genetic screening for
donor, χ2(4) = 36.674, p <.001. There was a moderately strong association preference of
genetic screening for self and genetic screening for donor, φ = 0.554, p < .001.
2.4.3 Genetics knowledge. A seven question analysis highlighted respondents’
understanding of AR inheritance, inherited disorders, and genetic carrier screening (Table
2.3). Twenty-two respondents (37.9%) were able to achieve a perfect score of seven. A
majority (79.3%) were able to correctly answer five of the seven questions.
2.4.4 Genetic carrier screening opinions. Participants were asked to consider a
series of statements regarding genetic carrier screening results and disclose their level of
agreement for each statement. The results are summarized in Table 2.4 and Figures 2.1
and 2.2. A majority of women (69.4%) at least slightly agreed that if their donor has
negative testing for a condition, they would not be worried about the other genetic parent
(either herself or her partner) being a carrier for that condition. Fewer women (60.7%) at
least slightly agreed that if one genetic parent (either herself, her partner, or another
donor) has negative testing for a condition, they would not be worried about their donor
being a carrier for that condition.
When asked to compare aspects of donor selection, 23.3% of women at least
slightly agreed that the physical characteristics of their donor were more important to
them than genetic carrier screening results. More women (35.8%) at least slightly agreed
that their donor’s family history was more important to them than genetic carrier
screening results. Eleven women (19.6%) agreed that carrier screening results were

26

equally as important as donor family history, while only four (7.1%) said the same for the
physical characteristics of the donor.
2.4.5 Donor selection scenarios. Respondents were asked to consider four distinct
scenarios in which their donor, who met all of their physical and family history
requirements, had ECS and was found to be a carrier of one of four different AR
conditions: hereditary hemochromatosis, Usher syndrome, Bardet-Biedl syndrome
(BBS), and GRACILE syndrome. Descriptions of each condition were provided
(Appendix B). An independent-samples t-test was run to determine if there were
statistically significant differences in how women answered a series of questions
regarding use of a donor, between four distinct conditions. The results are summarized in
Table 2.5.
The first question asked whether they would proceed with the donor, provided
that the other genetic parent had negative screening for the condition. More women were
comfortable proceeding with a donor who was a carrier for hemochromatosis (M = 1.17,
SD = 0.38, t (47) = 21.46, p = <0.001) than for any other condition. Next, women were
asked to consider whether they would give up an important physical or social
characteristic in order to proceed with a donor free of carrier status for each condition.
More women said that they would give up an important attribute in order to find a donor
that was not a carrier for Usher syndrome (M = 1.28, SD = 0.46, t (45) = 19.11, p =
<0.001), BBS (M =1.28, SD = 0.46, t (45) = 19.11, p <0.001), or GRACILE syndrome
(M = 1.39, SD = 0.49, t (45) = 19.12, p = <0.001), than for hemochromatosis. They were
then asked whether they would prefer the donor who tested positive for each condition
but negative for the remaining ECS panel, or a donor who was only screened for four
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conditions but was negative for all four. More women said they would rather proceed
with a donor who was only screened for four conditions, when comparing it to a donor
who was a carrier for Usher syndrome (M = 1.39, SD = 0.49, t (45) = 19.12, p = <0.001),
BBS (M = 1.47, SD = 0.50, t (44) = 19.50, p = <0.001), or GRACILE (M = 1.43, SD =
0.50, t (45) = 19.42, p = <0.001), than for hemochromatosis. Finally, they were asked
about their level of worry about the chance of their child being an unaffected carrier of
each condition. More women reported being worried about the chance of their child being
an unaffected carrier for Usher syndrome (M = 2.46, SD = 0.86, t (45) = 19.34, p =
<0.001), BBS (M = 2.50, SD = 0.84, t (45) = 20.27, p = <0.001), and GRACILE (M =
2.61, SD = 0.95, t (45) = 18.55, p = <0.001), than for hemochromatosis.
2.4.6 Open-ended responses. For each condition and corresponding set of questions,
women were given the opportunity to provide their overall thoughts about the donor.
Grounded theory methods revealed these major themes: (1) level of concern; (2) carrier
status of offspring; and (3) knowledge of genetic evaluation.
Theme 1: Level of concern.
Women voiced varying levels of concern for each donor. Most women were not
worried about their donor being a carrier for hemochromatosis, citing the mild nature of
the condition and the ease of treatment for affected individuals. Of the women who
provided their own input, 75% (24/32) stated that they would have little to no concern
using a donor who was a carrier for hemochromatosis. One respondent explained, “If he
was a carrier for one easily treatable disease, I would likely go for it.” As long as the
donor met all of their other criteria, many women felt that a donor who was a carrier for
hemochromatosis would be a strong candidate.
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“If all other desired attributes were present, and there were no other donors
who matched up, I would still select this donor. I feel the odds of inherited
health problems in his potential offspring are low, and at least he has been
pretty thoroughly screened. Natural conceptions do not usually have this
level of genetic screening.”
In contrast, few women stated that they would use a donor who was a carrier for
Usher syndrome, BBS, or GRACILE syndrome without concern. Regarding a donor who
was a carrier for Usher syndrome, one woman explained:
“My opinions of this donor are tainted by knowing that he tested positive as
a carrier for a condition with such severe effects. Just the knowledge of the
positive test creates a paranoia that potential offspring could develop or pass
on the condition.”
Women were generally well informed of the low overall risk for an affected
pregnancy with only one parent as a carrier but felt uncomfortable with the severity of
Usher, BBS, and GRACILE: “Low chance but the condition is too severe to knowingly
use a donor who is a carrier.”
Theme 2: Carrier status of offspring.
Many women mentioned their concerns about their offspring with each donor
being a carrier for the respective condition. For a donor who is a carrier of
hemochromatosis, respondents’ concerns revolved around testing the carrier status of any
offspring with that donor. Women felt that allowing them to inform their child of any
reproductive risks would be beneficial for them:
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“I would want to do more research into how it would affect them and
knowing that [the donor] is a carrier for it I would want to get my child with
them tested so that they can be fully informed before they decide to have
kids.”
In regard to donors who were carriers of Usher, BBS, or GRACILE, however,
women expressed considerable concern for their children being carriers. Again, severity
of disease often influenced this concern: “I would want to minimize the risk of my child
being a carrier for any condition that substantially reduces life expectancy.”
Theme 3: Knowledge of genetic evaluation.
There was a spectrum of opinions on the level of genetic screening the
hypothetical donors were receiving. A few women discussed the “unknown” in
pregnancies that were achieved without donor gametes, and one woman expanded by
stating, “I would rather the known than the unknown so if I know that it is a possibility
then I can plan for it and make sure my child is tested so they know if they are a carrier.”
Some women mentioned that guidance from their clinic would be beneficial in helping
them to decide to proceed with a donor: “I would consider this donor if he met all my
other requirements but would want to talk with a genetic counselor first,” and “[if] the
advice from my clinic was positive, I would feel reassured.”
One woman was uncomfortable with the decision to reject a donor based on
genetic carrier screening results. She explained:
“Children created without the use of donor sperm have the chance of being
affected by many disorders. The worry of using genetic testing to select a
donor is a bit like creating ‘designer babies.’ I would choose this donor
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based on a combination of traits particularly their openness to contact with
the child after birth, not based on the fact that they have completed genetic
testing.”
This participant’s responses remained consistent through the different donors, stating, “I
struggle to understand why someone would choose a donor or disregard a donor based on
a genetic test result.”
2.4.7 Ranking of donors. Participants were asked to rank five donors, based on how
likely they were to choose that donor based on genetic screening results (Figure 2.3). A
one-sample Kolmogorov-Smirnov test was performed to determine if there were
statistically significant differences in rankings between donors based on genetic screening
results. There were statistically significant differences (p <0.01), with individuals ranking
donor 2 first, donor 3 second, donor 1 third, donor 5 fourth, and donor 4 fifth (Table 2.6).
One woman reported that she had no preference regarding these donors, and six women
preferred not to select one of these donors at all.
The women were then asked to identify factors that influenced their ranking of the
donors. The results are summarized in Table 2.7. The severity of disorder was the most
influential factor, followed by the number of tested conditions.
2.4.8 Utility of genetic counselors. Women were provided with the National Society
of Genetic Counselors’ (NSGC) description of genetic counseling and asked to consider
the utility of genetic counselors in explaining carrier screening during the donor selection
process. Most women (53.3%) reported that it would be extremely helpful to have a
genetic counselor explain carrier screening to them. An additional 40% of women said
that it would be helpful or somewhat helpful. One person (2.2%) reported that she
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received enough information from someone at her donor clinic/program who was not a
genetic counselor.
2.5 Discussion
This is the first study to assess the opinions of intended parents regarding ECS of
gamete donors. There are currently limited consensus guidelines for genetic carrier
screening of donors. Therefore, there is much variability in how gamete donors are
screened at different clinics. Study findings have potential implications for implementing
ECS in a gamete donation setting. This study explored the perspectives of recipients of
donor gametes to gain insight into how much genetic information they may prefer to
receive about their potential donors and how they would utilize the results.
2.5.1 Preferences for ECS. Most of the participants preferred ECS over traditional
ethnicity-based screening, even more so for their donor than for themselves. This finding
was to be expected, since individuals are expending resources to utilize gamete donors,
and thus, may have a stronger preference for a higher level of genetic screening.
Additionally, there is an added element of choice when considering genetic screening of
donors versus screening of self or partner. Whereas a known carrier status in a donor may
impact a recipient’s choice of donor, there is no similar choice when carrier status is
identified in self or partner.
The preference for obtaining a higher level of genetic information has been
observed in other reproductive settings. A 2015 study explored women’s preferences for
prenatal testing, and found that pregnant women were inclined to choose a test that
offered the most information on the chromosomal status of their unborn child (Beulen et
al.). In this study, pregnant women placed the highest value on the level of information
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gained from prenatal tests, compared to other qualities of the test, such as minimum age
of gestation at which the test is offered, and waiting time for results.
In line with their carrier screening preferences, more of our participants felt they
would worry if their donor was a carrier of a gene mutation than if she or her partner was.
This may again relate to the element of choice, or it may indicate that recipients feel that
donors should be free of risk for genetic disease overall. Anecdotally, recipients are often
uncomfortable upon learning about positive carrier status of a previously chosen donor
(A. Besser & L. Isley, personal communication, March 15, 2017). It is reasonable to
believe they feel that given a choice, they would choose not to put their child at risk for
being a carrier of a genetic condition. Additionally, there may be an unrealistic
expectation for a donor to be genetically “perfect,” and once their chosen donor has been
identified as a carrier, he/she may no longer fit their description of the ideal donor. This
idea of a genetically “perfect” individual is unrealistic because as studies have shown, up
to 85% of individuals may be identified as a carrier for an AR condition on ECS panels
(Lazarin et al., 2013; Franasiak et al., 2016; Martin et al., 2015; Abuli, RodriguezSantiago, & Coroleu, 2016).
Only 19.6% (11/56) of women felt that the donor’s family history was as
important as genetic carrier screening results. This suggests potential lack of genetic
understanding, given the multifactorial nature of most common health problems and the
importance of family history assessment as the sole way of determining risk for these. In
one study, multifactorial conditions in donor-conceived offspring were documented to
occur at a higher frequency than AR conditions (Isley, et al., 2016). One of the concerns
of ECS is that there may be a false understanding that it tests for “everything,” and more
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education into the limitations of ECS may be warranted. Patients need to be properly
counseled that ECS is a valuable tool used to detect carriers of AR conditions; however,
it is unable to reduce the risks for most autosomal dominant (AD) and multifactorial
conditions. It is therefore important to recognize that ECS does not replace assessment of
familial risk or formal genetic counseling.
2.5.2 Donor preferences based on carrier screening results. Our study found that
unsurprisingly, women were more likely to proceed with a donor who was a carrier for
hemochromatosis, a relatively mild condition, than for Usher, BBS, or GRACILE. In
general, women were comfortable proceeding with a donor who was a carrier for
hemochromatosis, and would not give up an important attribute to find a donor who was
not a carrier. The rejection rate of a donor who was a carrier for hemochromatosis was
16.7%, compared to Usher, BBS, or GRACILE, which had rejection rates of 63%,
60.9%, and 60.9%, respectively. Importantly, 39.1%, 46.7%, and 43.5% of women,
respectively, preferred a donor who was only screened for four conditions and negative
for all four, over these donors who were screened for 300 conditions and positive for
Usher, BBS, or GRACILE (Table 2.5). This is somewhat consistent with a 2016 study,
which found that when sperm donors received supplemental screening (at the request of
their recipients, who had been identified as carriers, often through ECS) and found to be a
carrier of the same condition, the majority of recipients chose another, often untested,
donor (Callum & Isley).
Many respondents expressed concern over their offspring with a potential donor
being a carrier for a genetic condition. It was difficult to ascertain from this study the
reasons behind this concern – whether recipients were concerned with reproductive risk
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for their offspring or the chance for their offspring to develop the condition. Some
participants mentioned the carrier status of their offspring in their open-ended responses;
however, the meanings behind their statements were often unclear. Future studies would
benefit from interviews with recipients, to extrapolate their true feelings and concerns.
In ranking donors based on carrier screening results, women ranked a donor who
was a carrier for hemochromatosis as their first choice. Surprisingly, a donor who was
only screened for four conditions (and found to be negative for all four) ranked higher
than a donor who was a carrier for either BBS or GRACILE, both rare conditions with
relatively low carrier frequencies, and negative for the remaining 299 conditions. Women
most often cited the severity of condition as an influential factor in these donor choices.
These results suggest that, in general, women are comfortable with a donor who is a
carrier of a mild condition or a donor who has had limited testing, and less comfortable to
proceed with a donor who is a carrier for a more severe condition. This is supported by
the relatively high rejection rates of donors who were carriers for Usher, BBS, or
GRCAILE, compared to hemochromatosis, and the tendency for women to give up an
important physical or social characteristic to find a donor who was free of carrier status
of these conditions. This is interesting because it contradicts the participants’ interest in
ECS, preferred over ethnicity- or family history-based screening. Women may state their
desires for more genetic information on their donors (i.e. ECS); however, many may not
be prepared for the realistic outcomes of ECS, which would identify the majority of
donors as carriers for a genetic condition. It appears there may be an unrealistic
expectation for a donor who meets all of a recipients’ physical and social characteristic
requirements and who screens negative on a panel consisting of several hundred
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conditions. In our study, eight women stated that they would not proceed with a donor
who was a carrier for hemochromatosis, even if the other genetic parent was not a carrier.
This is interesting given the relatively mild nature and ease of treatment of the condition,
in addition to the low statistical risk of having an affected child when only one genetic
parent is identified as a carrier. Therefore, more research could be done to elicit reasoning
behind rejection of these donors.
Anecdotally, from speaking with genetics professionals who have experience in
gamete donation programs, intended parents may proceed with a donor who is a known
carrier of a genetic disorder for a variety of reasons. In egg donation, intended parents
often experience a level of attachment to their egg donors. In general, a more limited pool
of egg donors exists as compared to sperm donors; thus, recipients using donor eggs
typically have fewer options than recipients using donor sperm. Couples may experience
difficulty finding an egg donor who matches their desired ethnicity or other physical
characteristics, unlike in sperm donation, where there tends to be many more donor
choices available (A. Besser & L. Isley, personal communication, March 15, 2017).
In sperm donation, couples who learn their donor is a carrier for an AR disorder
after they have already chosen to use that donor’s gametes may decide to continue using
that donor for a couple of reasons. Financially, recipients often purchase multiple vials of
sperm from one donor at one time. Discarding the vials upon knowledge of genetic risk
could mean a significant financial loss, which may not be an option for some recipients.
Another reason for continuing to use a donor is the opportunity to provide a full genetic
sibling for their donor-conceived child, which is an important factor for some families
(A. Besser & L. Isley, personal communication, March 15, 2017).
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There may be psychological factors involved in donor selection that do not
equally apply to parents who conceive without the use of a donor. As an intended parent
actively chooses a particular donor (compared to parents who conceive with their own
gametes), any actual or potential adverse health outcomes in a donor-conceived child
may result in an additional burden of guilt for making the “wrong” choice. Most parents
would likely agree that if given the choice, they would choose not to put their child at risk
of being a carrier for any genetic conditions (A. Besser & L. Isley, personal
communication, March 15, 2017).
Our findings suggest that implementation of ECS in a gamete donation program
would significantly alter clinical decision making. Most of the women in our study stated
that they would be uncomfortable proceeding with a donor who was a carrier for a severe
genetic condition. The ACOG Committee on Genetics recently published new guidelines
and points to consider on ECS. These guidelines highlight that conditions included on
expanded panels should have a well-defined phenotype, have a detrimental effect on
quality of life, cause cognitive or physical impairment, require surgical or medical
intervention, or have an onset early in life (2017). Including milder conditions such as
hemochromatosis on expanded panels may be going against established guidelines for
ECS. It is important to remember that the inclusion of a condition on an expanded panel
does not necessarily validate its appropriateness on that panel, and gamete programs
should be especially wary of offering expanded panels which include conditions that do
not fully comply with established guidelines.
It is important to recognize the importance of proper genetic evaluation of the
intended parent, as genetic risk is not dependent solely on the donor. Genetic evaluation
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of both genetic parents is necessary to perform accurate risk assessment and provide
information for recipients to make the most informed decision about a donor.
2.5.3 Genetics knowledge. A genetics knowledge quiz was performed to assess
potential areas of improvement in education about genetic disease. Twenty-two
respondents (37.9%) were able to correctly answer all seven questions, indicating that
they had a fair understanding of the nature of genetic diseases. However, up to 37.2% of
respondents provided incorrect answers to questions regarding the implications of various
carrier screening results (questions 1, 2, 5-7, Table 2.3). We speculated that poor overall
understanding of carrier screening could affect women’s preferences for or against a
donor who was a carrier of a genetic condition; however, no significant differences were
found between those who answered more questions correctly and those who answered
less questions correctly. Further studies could include more detailed analyses on how
genetics knowledge affects perspectives towards carrier screening results and donor
selection. Additionally, increased education about carrier screening in this population
may be beneficial to ensure that recipients are making informed decisions.
2.5.4 Study limitations. The major limitation of this study was the homogeneity of
participants. Most of the participants were Caucasian, educated women; the results
cannot be generalizable to the perspectives of all intended parents. It would be interesting
to gather the perspectives of men in this population. Similarly, as most of the results
represent the views of women who utilized donor sperm to become single mothers, they
are not generalizable to the population of all individuals and couples who use donor
gametes. Additionally, because very few respondents reported the use of donor eggs,
comparisons could not be made between those who utilize donor sperm and those who
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utilize donor eggs. As mentioned previously, there are fewer options for egg donors as
there are for sperm donors, and this may have a significant impact on whether carrier
status of a donor alters a recipient’s choice to continue with that donor.
Our study attempted to discern differences in the way carrier screening was
perceived based on which countries the participants lived in. Because the majority of
participants resided in the United States, no such comparisons could be made. Carrier
screening practices differ in countries around the world; therefore, general perceptions of
carrier screening may differ. In some countries, such as Iran, Turkey, Saudi Arabia, and
Cyprus, carrier screening for certain conditions (i.e. beta thalassemia) is mandatory and
routinely performed in premarital couples. Some countries, such as Greece, Iran, and
Italy, provide information about carrier screening through mass media to increase
knowledge among the general population (Cousens et al., 2010). In these countries,
carrier screening is normalized and general attitudes toward carrier screening may be
more positive. It would be interesting to compare perspectives of gamete recipients
residing in these countries, to see whether there is a difference in preference when carrier
screening is normalized throughout the country.
Lastly, a limitation in our study was in the interpretation of open-ended responses
of participants. Because their responses were written rather than obtained from oral
interviews, their responses could not be clarified and there could be some discrepancy
between what the participants meant and how their responses were interpreted. Future
studies may utilize interviews to further clarify and understand the views of intended
parents.
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2.5.5 Genetic counseling practice implications. Women in our study felt it would be
helpful to speak with a genetic counselor about reproductive risk in the setting of gamete
donor selection. Future studies may focus on how genetic counseling could be helpful in
gamete donation programs. It would be interesting to see whether genetic counseling
during the donor selection process can impact a recipient’s comfort level with choosing a
donor who was identified as a carrier for a genetic condition. Allowing the recipients
access to a genetic counselor to have discussions about residual risk, carrier frequencies,
and other details surrounding carrier screening may be beneficial in gamete donation
programs to ensure that they are making the most informed decisions.
2.6 Conclusion
Due to the emergence of new technologies and decreasing costs, carrier screening
for hundreds of conditions at one time has become readily accessible. Gamete donation
programs are an ideal setting for ECS, as all screening occurs in the preconception
period, when carrier screening is most beneficial to maximize reproductive choice. With
limited current consensus guideline recommendations for the level of carrier screening
performed in the gamete donor population, updated guidelines may benefit from
perspectives of intended parents. Our study found that although recipients were interested
in ECS for their potential donors, they were uncomfortable choosing a donor who was a
carrier for an AR condition. This would significantly limit the available donor pool, as
ECS would identify most individuals as a carrier for at least one condition. It seems that
in most cases, ECS in a gamete donation program would alter clinical decision making
for the recipients.
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There seemed to be a disconnect between what recipients think they desired and
the level of information they would be comfortable with. This could be due to a lack of
overall understanding of carrier screening, and/or an unrealistic expectation that donors
should test negative when screened for carrier status of hundreds of conditions, despite
the reality that most individuals screened will have at least one positive result. Increased
knowledge among intended parents on the frequency and implications of positive carrier
screening results is necessary before implementation of ECS in gamete donation
programs would be successful. Additionally, intended parents need to be properly
counseled that although ECS is a valuable tool to detect carriers of AR conditions, it is
unable to reduce the risks for most AD and multifactorial conditions. Therefore, it is
important to recognize that ECS does not replace genetic counseling or assessment of
familial risk.
Recipients may benefit from increased genetic education about carrier
frequencies, residual risk, and other details surrounding genetic carrier screening. As
expressed by our participants, access to genetic counseling could be an integral part of
the gamete donation process. Proper counseling can aid in decreasing the gaps in
knowledge among intended parents regarding carrier screening, and ensure that recipients
are making the most informed decisions.
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Table 2.1 Patient demographics
Number of
participants (%)

Demographic
Gender
Female
Age
18-35
36-45
46+
Total
Relationship status
Single
Married
Partnered, not married
Total
Ethnicity/ancestry
Caucasian
Hispanic/Latino
Jewish
Mediterranean (Italian, Greek)
Middle Eastern
Native American
Total
Country of residence
Australia
Canada
United Kingdom
United States
Total
Highest education level
High school diploma/GED
Some college
Associate’s degree
Bachelor’s degree
Some graduate school
Graduate degree (Master’s, PhD, MD, JD, etc.)
Total
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58 (100)
14 (24.6)
36 (63.2)
7 (12.3)
57 (100)
47 (81.0)
10 (17.2)
1 (1.7)
58 (100)
54 (93.1)
2 (3.4)
6 (10.3)
1 (1.7)
1 (1.7)
1 (1.7)
58 (100)
1 (1.7)
10 (17.2)
2 (3.4)
45 (77.6)
58 (100)
2 (3.4)
2 (3.4)
2 (3.4)
11 (19.0)
3 (5.2)
38 (65.5)
58 (100)

Table 2.2 Personal history with use of donor gametes
Number of
participants (%)
Ever attempted to conceive with an egg or sperm donor in the past
Yes, and had a live birth
38 (65.5)
Yes, and have an ongoing pregnancy
6 (10.3)
Yes, but the pregnancy did not result in a live birth
3 (5.2)
Yes, but pregnancy was not achieved
4 (6.9)
No, I have not attempted to conceive with a donor
7 (12.1)
Total
58 (100)
Currently seeking egg or sperm donor
Yes – seeking egg donor
1 (1.7)
Yes – seeking sperm donor
10 (17.2)
No
47 (81.0)
Total
58 (100)
Reason for using an egg and/or sperm donor
Female factor infertility
10 (17.2)
Male factor infertility
4 (6.9)
Single mother
48 (82.8)
LGBTQ individual or couple
6 (10.3)
Genetic condition in me/my partner
1 (1.7)
Total
58 (100)
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Table 2.3 Genetics knowledge results
Question (True/False)
If both genetic parents are found to be carriers of
the same mutation, the child will definitely have
the disorder
If my donor is a carrier of a genetic mutation and
I (or my partner) am not, the child will likely not
be affected by the disorder
Healthy parents can have a child with an inherited
disorder
Some genetic disorders occur more commonly in
certain ethnic groups
If somebody is found to be a carrier of an
autosomal recessive disorder, that person will
develop the disease
If genetic carrier screening finds no mutations in
one genetic parent, any child from that parent is
not at risk for any conditions
If neither parent is found to be carriers of a
mutation, their child definitely will not develop a
genetic condition
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Correct
Answer

Number of
correct answers
(%)

False

42 (72.4)

True

39 (67.2)

True

58 (100)

True

57 (98.3)

False

50 (86.2)

False

47 (81.0)

False

37 (63.8)

Table 2.4 Opinions about genetic carrier screening results
Statement
I am not worried about
the other genetic parent
(non-donor) being a
carrier for a genetic
condition if my donor
has negative testing for
that condition (n=49)
I am not worried about
my donor being a
carrier of a genetic
condition if the other
genetic parent (donor
or non-donor) has
negative testing for that
condition (n=56)
Statement

Strongly
Agree

Strongly
Agree

Agree

Slightly
Agree

Slightly
disagree

Disagree

Strongly
Disagree

7 (14.3)

20
(40.8)

7
(14.3)

9 (18.4)

5 (10.2)

1 (2.0)

8 (14.3)

14
(25.0)

12
(21.4)

10
(17.9)

8 (14.3)

4 (7.1)

Agree

Slightly
Agree

Slightly
disagree

Disagree

Strongly
Disagree

They are
equally
important

7
(12.5)

20
(35.7)

12
(21.4)

4 (7.1)

10
(17.9)

12
(21.4)

3 (5.4)

11
(19.6)

The physical
characteristics
of my donor
are more
important to
10
0 (0)
3 (5.4)
me than
(17.9)
genetic
carrier
screening
results (n=56)
My donor’s
family history
is more
important to
9
me than
3 (5.4) 8 (14.3)
(16.1)
genetic
carrier
screening
results (n=56)
Note: Data are expressed as n (%).
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Table 2.5 Donor selection scenarios
Hemochromatosis
Usher
BBS
GRACILE
Would proceed with donor to build family (provided negative testing for other
genetic parent)
Yes
40 (83.3)
17 (37.0) 18 (39.1)
18 (39.1)
No
8 (16.7)
29 (63.0) 28 (60.9)
28 (60.9)
Would give up an important attribute unrelated to health to proceed with donor
free of carrier status
Yes
19 (39.6)
33 (71.7) 33 (71.7)
28 (60.9)
No
29 (60.4)
13 (28.3) 13 (28.3)
18 (39.1)
Donor preference
This donor (screened for
42 (87.5)
28 (60.9) 24 (53.3)
26 (56.5)
300, positive for 1)
Other donor (screened for
6 (12.5)
18 (39.1) 21 (46.7)
20 (43.5)
4, negative for all)
Level of concern for offspring being unaffected carrier
Not worried at all
14 (29.2)
6 (13.0)
4 (8.7)
4 (8.7)
Slightly worried
28 (58.3)
18 (39.1) 21 (45.7)
21 (45.7)
Worried
5 (10.4)
17 (37.0) 15 (32.6)
10 (21.7)
Extremely worried
1 (2.1)
5 (10.9)
6 (13.0)
11 (23.9)
Note: Data are expressed as n (%).
Table 2.6 Ranking of donors
Ranking
1
2
3
4
5

Donor
2: tested for 300 conditions, carrier for hemochromatosis
3: tested for 300 conditions, carrier for Usher syndrome
1: tested for 4 conditions, negative for all 4
5: tested for 300 conditions, carrier for GRACILE
4: tested for 300 conditions, carrier for BBS

N
42
39
38
39
39

Mean
1.24
2.92
3.13
3.79
3.87

Table 2.7 Factors influencing ranking of donors
Factor
Number of tested conditions
Severity of disorder for which he/she is a carrier
Incidence of disorder for which he/she is a carrier
Availability of testing for me/my partner to assess the
chance that I/he/she is not a carrier of the same
disorder
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Number of participants
(%)
27 (46.6)
42 (72.4)
26 (44.8)
16 (27.6)

I am not worried about the other genetic parent (nondonor) being a carrier for a genetic condition if my
donor has negative testing for that condition

7

I am not worried about my donor being a carrier of a
genetic condition if the other genetic parent (donor or
non-donor) has negative testing for that condition

8

Strongly Agree

Agree

Slightly Agree

20

7

14

9

12

Slightly Disagree

Disagree

10

5 1

8

4

Strongly Disagree

Figure 2.1
On a scale from strongly agree to strongly disagree, participants’ level of agreement on
statements about genetic carrier screening in gamete donors.

The physical characteristics of my donor are more
important to me than genetic carrier screening results

3

10

4

My donor’s family history is more important to me than
genetic carrier screening results

3

8

9

Strongly Agree

Agree

7

20

11

10

12

12

3

Slightly Agree

They Are Equally Important Slightly Disagree

Disagree

Strongly Disagree

Figure 2.2
On a scale from strongly agree to strongly disagree, participants’ level of agreement on
statements about genetic carrier screening in gamete donors.
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40
35
30
25
20
15
10
5
0
1

2

3

4

donor tested for 4 conditions, negative for all 4
donor tested for 300 conditions, carrier for hemochromatosis
donor tested for 300 conditions, carrier for Usher syndrome
donor tested for 300 conditions, carrier for BBS
donor tested for 300 conditions, carrier for GRACILE

Figure 2.3
Parcipants’ rankings of donors based on genetic carrier screening results.
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5

Chapter 3: Conclusion
Due to the emergence of new technologies and decreasing costs, carrier screening for
hundreds of conditions at one time has become readily accessible. Gamete donation
programs are an ideal setting for expanded carrier screening (ECS), as all screening
occurs in the preconception period, when carrier screening is most beneficial to maximize
reproductive choice. With limited current consensus guideline recommendations for the
level of carrier screening performed in the gamete donor population, updated guidelines
may benefit from perspectives of intended parents. Our study found that although
recipients were interested in ECS for their potential donors, they were uncomfortable
choosing a donor who was a carrier for an autosomal recessive (AR) condition. This
would significantly limit the available donor pool, as ECS would identify most
individuals as a carrier for at least one condition. It seems that in most cases, ECS in a
gamete donation program would alter clinical decision making for the recipients.
There seemed to be a disconnect between what recipients think they desired and
the level of information they would be comfortable with. This could be due to a lack of
overall understanding of carrier screening, and/or an unrealistic expectation that donors
should test negative when screened for carrier status of hundreds of conditions, despite
the reality that most individuals screened will have at least one positive result. Increased
knowledge among intended parents on the frequency and implications of positive carrier
screening results is necessary before implementation of ECS in gamete donation
programs would be successful. Additionally, intended parents need to be properly
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counseled that although ECS is a valuable tool to detect carriers of AR conditions, it is
unable to reduce the risks for most autosomal dominant and multifactorial conditions.
Therefore, it is important to recognize that ECS does not replace genetic counseling or
assessment of familial risk.
Recipients may benefit from increased genetic education about carrier
frequencies, residual risk, and other details surrounding genetic carrier screening. As
expressed by our participants, access to genetic counseling could be an integral part of
the gamete donation process. Proper counseling can aid in decreasing the gaps in
knowledge among intended parents regarding carrier screening, and ensure that recipients
are making the most informed decisions.

50

References
Abulí, A., Rodríguez-santiago, B., & Coroleu, B. (2016). NGS-based assay for the
identification of individuals carrying recessive genetic mutations in reproductive
medicine, 1–28. http://doi.org/10.1002/humu.22989
American College of Obstetricians and Gynecologists’ Committee on Genetics. (2009).
Preconception and prenatal carrier screening for genetic diseases in individuals of
Eastern European Jewish descent. Obstetrics & Gynecology, 114(442), 950–953.
American College of Obstetricians and Gynecologists’ Committee on Genetics. (2017).
Carrier screening in the age of genomic medicine (690). Obstetrics &
Gynecology, 129, e35-40.
American Society for Reproductive Medicine. (2013). Recommendations for gamete and
embryo donation: A committee opinion. Fertility and Sterility, 99(1).
http://doi.org/10.1016/j.fertnstert.2012.09.037
Baker, V. L., Rone, H. M., & Adamson, G. D. (2008). Genetic evaluation of oocyte
donors: recipient couple preferences and outcome of testing. Fertility and
Sterility, 90(6), 2091–2098. http://doi.org/10.1016/j.fertnstert.2007.10.069
Benn, P., Chapman, A. R., Erickson, K., Defrancesco, M. S., Wilkins-Haug, L., Egan, J.
F. X., & Schulkin, J. (2014). Obstetricians and gynecologists’ practice and
opinions of expanded carrier testing and noninvasive prenatal testing. Prenatal
Diagnosis, 34(2), 145–152. http://doi.org/10.1002/pd.4272
Beulen, L., Grutters, J. P. C., Faas, B. H. W., Feenstra, I., Groenewoud, H., Vugt, J. M.
G. Van, & Bekker, M. N. (2015). Women’s and healthcare professionals’
preferences for prenatal testing: a discrete choice experiment. Prenatal Diagnosis,
35, 549–557. http://doi.org/10.1002/pd.4571
Callum, P., & Isley, L. (2016). Impact of expanded carrier screening panels on gamete
donor screening practices. Fertility and Sterility, 105(2), e16.
http://doi.org/10.1016/j.fertnstert.2015.12.061
Centers for Disease Control and Prevention. (2015, Feb 06). Fast Facts – Infertlity.
Retrieved from http://www.cdc.gov/nchs/fastats/infertility.htm

51

Cho, D., McGowan, M. L., Metcalfe, J., & Sharp, R. R. (2013). Expanded carrier
screening in reproductive healthcare: Perspectives from genetics professionals.
Human Reproduction, 28(6), 1725–1730. http://doi.org/10.1093/humrep/det091
Cousens, N. E., Gaff, C. L., Metcalfe, S. A., & Delatycki, M. B. (2010). Carrier screening
for Beta-thalassaemia: a review of international practice. European Journal of
Human Genetics, 18(10), 1077–1083. http://doi.org/10.1038/ejhg.2010.90
Edwards, J. G., Feldman, G., Goldberg, J., Gregg, A. R., Norton, M. E., Rose, N. C.,
Schneider, A., Stoll, K., Wapner, R., & Watson, M. S. (2015). Expanded carrier
screening in reproductive medicine—Points to consider. Obstetrics &
Gynecology, 125(3), 653–662. http://doi.org/10.1097/AOG.0000000000000666
Ethics Committee of the American Society for Reproductive Medicine. (2014). Interests,
obligations, and rights in gamete donation: A committee opinion. Fertility and
Sterility, 102(3), 675–681. http://doi.org/10.1016/j.fertnstert.2014.06.001
Franasiak, J. M., Olcha, M., Bergh, P. A., Hong, K. H., Werner, M. D., Forman, E. J.,
Zimmerman, R. S., Scott, R. T. (2016). Expanded carrier screening in an infertile
population: how often is clinical decision making affected?, (January), 1–5.
http://doi.org/10.1038/gim.2016.8
Frith, L., Sawyer, N., & Kramer, W. (2012). Forming a family with sperm donation: A
survey of 244 non-biological parents. Reproductive BioMedicine Online, 24(7),
709–718. http://doi.org/10.1016/j.rbmo.2012.01.013
Gil-Arribas, E., Herrer, R., & Serna, J. (2016). Pros and cons of implementing a carrier
genetic test in an infertility practice. Current Opinion in Obstetrics &
Gynecology, 28. http://doi.org/10.1097/GCO.0000000000000272
Grody, W. W., Thompson, B. H., Gregg, A. R., Bean, L. H., Monaghan, K. G.,
Schneider, A., & Lebo, R. V. (2013). ACMG position statement on
prenatal/preconception expanded carrier screening. American College of Medical
Genetics, 15(6), 482–3. http://doi.org/10.1038/gim.2013.47
Gross, S. J., Pletcher, B. a, & Monaghan, K. G. (2008). Carrier screening in individuals
of Ashkenazi Jewish descent. Genetics in Medicine : Official Journal of the
American College of Medical Genetics, 10(1), 54–56.
http://doi.org/10.1097/GIM.0b013e31815f247c
Gunn, D. D., & Bates, G. W. (2016). Evidence-based approach to unexplained infertility:
a systematic review. Fertility and Sterility.
http://doi.org/10.1016/j.fertnstert.2016.02.001
Haque, I. S., Lazarin, G. A., Kang, H. P., Evans, E. A., Goldberg, J. D., & Wapner, R. J.
(2016). Modeled fetal risk of genetic diseases identified by expanded carrier

52

screening. Journal of the American Medical Association, 316(7), 734–742.
http://doi.org/10.1001/jama.2016.11139
Henneman, L., Borry, P., Chokoshvili, D., Cornel, M. C., van El, C. G., Forzano, F., Hall,
A., Howard, H. C., Janssens, S., Kayserili, H., Lakeman, P., Lucassen, A.,
Metcalfe, S. A., Vidmar, L., de Wert, G., Dondorp, W. J., & Peterlin, B. (2016).
Responsible implementation of expanded carrier screening. European Journal of
Human Genetics, (November 2015), 1–12. http://doi.org/10.1038/ejhg.2015.271
Hershberger, P. (2004). Recipients of oocyte donation: an integrative review. J Obstet
Gynecol Neonatal Nurs, 33(5), 610–621.
http://doi.org/10.1177/0884217504268524
Holtkamp, K. C. A., van Maarle, M. C., Schouten, M. J. E., Dondorp, W. J., Lakeman, P.,
& Henneman, L. (2016). Do people from the Jewish community prefer ancestrybased or pan-ethnic expanded carrier screening? European Journal of Human
Genetics, 24(2), 171–177. http://doi.org/10.1038/ejhg.2015.97
Holton, A. E., Canary, H. E., & Wong, B. (2016). Business and breakthrough: framing
(expanded) genetic carrier screening for the public. Health Communication, 0(0),
1–8. http://doi.org/10.1080/10410236.2016.1196515
Isley, L., & Callum, P. (2013). Genetic evaluation procedures at sperm banks in the
United States. Fertility and Sterility, 99(6), 1587–1591.
http://doi.org/10.1016/j.juro.2013.10.014
Isley, L., Falk, R. E., Shamonki, J., Sims, C. A., & Callum, P. (2016). Management of the
risks for inherited disease in donor-conceived offspring. Fertility and Sterility,
(August), 1–6. http://doi.org/10.1016/j.fertnstert.2016.08.008
Janssens, S., Chokoshvili, D., Vears, D., De Paepe, A., & Borry, P. (2017). Attitudes of
European geneticists regarding expanded carrier screening. Journal of Obstetric,
Gynecologic, & Neonatal Nursing, 46(1), 63–71.
http://doi.org/10.1016/j.jogn.2016.08.012
Kingsmore, S. (2012). Comprehensive carrier screening and molecular diagnostic testing
for recessive childhood diseases. PLoS Currents.
http://doi.org/10.1371/4f9877ab8ffa9
Koroma, L., & Stewart, L. (2012). Infertility: evaluation and initial management. Journal
of Midwifery and Women’s Health, 57(6), 614–621. http://doi.org/10.1111/j.15422011.2012.00241.x
Lazarin, G. A., Haque, I. S., Nazareth, S., Iori, K., Patterson, A. S., Jacobson, J. L.,
Marshall, J. R., Seltzer, W. K., Patrizio, P., Evans, E. A., & Srinivasan, B. S.
(2013). An empirical estimate of carrier frequencies for 400+ causal Mendelian

53

variants: results from an ethnically diverse clinical sample of 23,453 individuals.
Genetics in Medicine : Official Journal of the American College of Medical
Genetics, 15(3), 178–86. http://doi.org/10.1038/gim.2012.114
Lazarin, G. A., Hawthorne, F., Collins, N. S., Platt, E. A., Evans, E. A., & Haque, I. S.
(2014). Systematic classification of disease severity for evaluation of expanded
carrier screening panels. PLoS ONE, 9(12), 1–16.
http://doi.org/10.1371/journal.pone.0114391
Lazarin, G. A., Detweiler, S., Nazareth, S. B., & Ashkinadze, E. (2015). Genetic
counselors’ perspectives and practices regarding expanded carrier screening after
Initial Clinical Availability. Journal of Genetic Counseling, 395–404.
http://doi.org/10.1007/s10897-015-9881-1
Lazarin, G. A., & Haque, I. S. (2015). Expanded carrier screening: A review of early
implementation and literature. Seminars in Perinatology, 40(1), 29–34.
http://doi.org/10.1053/j.semperi.2015.11.005
Leo, M. C., Mcmullen, C., Wilfond, B. S., Lynch, F. L., Reiss, J. A., Gilmore, M. J.,
Himes, P., Kauffman, T. L., Davis, J., Jarvik, G. P., Berg, J. S., Harding, C.,
Kennedy, K. A., Kostiner-Simposn, D., Quigley, D. I., Richards, C. S., Rope, A.
F., & Goddard, K. A. B. (2016). Patients’ ratings of genetic conditions validate a
taxonomy to simplify decisions about preconception carrier screening via genome
sequencing, (January), 574–582. http://doi.org/10.1002/ajmg.a.37477
Martin, J., Asan, Yi, Y., Alberola, T., Rodríguez-Iglesias, B., Jimínez-Almazán, J., Li,
Q., Du, H., Alama, P., Ruiz, A., Bosch, E., Garrido, N., & Simon, C. (2015).
Comprehensive carrier genetic test using next-generation deoxyribonucleic acid
sequencing in infertile couples wishing to conceive through assisted reproductive
technology. Fertility and Sterility, 104(5), 1286–1293.
http://doi.org/10.1016/j.fertnstert.2015.07.1166
Nazareth, S. B., Lazarin, G. A., & Goldberg, J. D. (2015). Changing trends in carrier
screening for genetic disease in the United States. Prenatal Diagnosis, 35(10),
931–935. http://doi.org/10.1002/pd.4647
Plantinga, M., Birnie, E., Abbott, K. M., Sinke, R. J., Lucassen, A. M., Schuurmans, J.,
Kaplan, S., Verkerk, M. A., Ranchor, A. V., & van Langen, I. M. (2016).
Population-based preconception carrier screening: how potential users from the
general population view a test for 50 serious diseases. European Journal of
Human Genetics, (October 2015), 1–7. http://doi.org/10.1038/ejhg.2016.43
Ready, K., Haque, I. S., Srinivasan, B. S., & Marshall, J. R. (2012). Knowledge and
attitudes regarding expanded genetic carrier screening among women’s healthcare
providers. Fertility and Sterility, 97(2), 407–413.
http://doi.org/10.1016/j.fertnstert.2011.11.007

54

Rose, N. C., & Wick, M. (2015). Current recommendations: Screening for Mendelian
disorders. Seminars in Perinatology, 40, 23–28.
http://doi.org/10.1053/j.semperi.2015.11.004
Rubin, L. R., De Melo-Martin, I., Rosenwaks, Z., & Cholst, I. N. (2015). Once you’re
choosing, nobody's perfect: Is more information necessarily better in oocyte donor
selection? Reproductive BioMedicine Online, 30(3), 311–318.
http://doi.org/10.1016/j.rbmo.2014.11.017
Sawyer, N., Blyth, E., Kramer, W., & Frith, L. (2013). A survey of 1700 women who
formed their families using donor spermatozoa. Reproductive BioMedicine
Online, 27(4), 436–447. http://doi.org/10.1016/j.rbmo.2013.07.009
Schneider, J. L., Goddard, K. A. B., Davis, J., Wilfond, B., Kauffman, T. L., Reiss, J. A.,
Gilmore, M., Himes, P., Lynch, F., Leo., M., & McMullen, C. (2015). “Is it worth
knowing?” Focus group participants’ perceived utility of genomic preconception
carrier screening. Journal of Genetic Counseling, 135–145.
http://doi.org/10.1007/s10897-015-9851-7
Schoen, C., Santolaya-Forgas, J., Genc, M., & Ashkinadze, E. (2015). Differential
utilization of expanded genetic screening tests in patients of reproductive ages
from private and academic practices. Journal of Perinatal Medicine, 43(6), 689–
693. http://doi.org/10.1515/jpm-2014-0160
Silver, A. J., Larson, J. L., Silver, M. J., Lim, R. M., Borroto, C., Spurrier, B., Morriss,
A., & Silver, L. M. (2016). Carrier screening is a deficient strategy for
determining sperm donor eligibility and reducing risk of disease in recipient
children. Genetic Testing and Molecular Biomarkers, 00(00), gtmb.2016.0014.
http://doi.org/10.1089/gtmb.2016.0014
Sunderam, S., Barfield, W. D., Kissin, D. M., Crawford, S. B., Folger, S. G., Jamieson,
D. J., & Warner, L. (2015). Assisted reproductive technology surveillance —
United States, 2000. MMWR Surveillance Summary, 64(11).
http://doi.org/10.15585/mmwr.ss6411a1

55

Appendix A – Invitation to Participate
Invitation to Participate: Recipients’ Perspectives Regarding Expanded Carrier Screening
Dear Potential Participant,
You are invited to participate in an anonymous master of science thesis research
study at the University of South Carolina School of Medicine. The objective of this study
is to determine how much genetic carrier screening information a recipient would prefer
to receive about their potential egg and sperm donors. The study will also aim to identify
factors that influence an intended parent’s choice of donor based on genetic screening
results.
We are inviting both parents of donor-conceived children and intended parents
currently in the process of selecting/using a donor to participate. Participation in this
study is meant to benefit intended parents by identifying whether increased education of
genetic screening options could improve the donor selection process. We believe that the
results of this study can add to the discussion concerning genetic screening of egg and
sperm donors, which could lead to greater consistency among donor screening practices.
If you decide to participate, you will be asked to complete an anonymous online
questionnaire about various issues surrounding the genetic screening of egg and sperm
donors. All responses are kept anonymous and confidential. The data collected may be
published or presented, but your responses will not be associated with any personally
identifying information. The survey will take approximately 15 minutes to complete, and
participation is completely voluntary. You do not have to answer any questions that you
do not wish to answer and you may discontinue the survey at any time. By completing
the survey, you are consenting that you have read and understand this information.
Thank you for your time and participation in this study. Your answers will help to
improve the donor screening and selection process for future parents. If you have any
questions, or would like more information, please contact me or my advisor, Janice
Edwards, using the contact information below. Thank you for considering participating in
this research project. Your input is invaluable and we appreciate your time.
Link to access survey: https://www.surveymonkey.com/r/LJLSDP9
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Erika Jackson
Genetic Counseling Intern
University of South Carolina School of
Medicine
Genetic Counseling Program
2 Medical Park, Suite 103
Columbia, SC 29203
(541) 729-9955
Erika.jackson@uscmed.sc.edu

Janice Edwards, MS, CGC
Clinical Professor and Director
University of South Carolina School of
Medicine
Genetic Counseling Program
2 Medical Park, Suite 103
Columbia, SC 29203
(803) 545-5706
Janice.edwards@uscmed.sc.edu
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Appendix B – Questionnaire

You are being asked to participate in this study if you are using or have previously used an egg
and/or sperm donor(s) to build your family. The purpose of this study is to explore the perspectives
of intended parents regarding the genetic testing of a gamete donor.
Your participation in this study will increase our understanding of the factors that influence the
decision to choose a donor based on their genetic screening results. We believe that the results of
this study can add to the discussion concerning genetic screening of egg and sperm donors, which
could lead to greater consistency among donor screening practices.
Your participation in the study is voluntary, and you can withdraw from the study at any time.
Participating in the study involves completing an online survey. The survey is anonymous, meaning
that we will not collect any personal information that could identify you or connect you to your
responses. The survey should take approximately 15 minutes to complete. Questions in the survey
will ask you about your perspectives regarding carrier screening of egg and sperm donors, as well
as your preferences of donors based on hypothetical genetic carrier screening results. There are
also some questions designed to assess your knowledge of genetic concepts.
This study is being conducted by Erika Jackson, a genetic counseling student at the University of
South Carolina Medical School for a Master’s Thesis project. Janice Edwards, a genetic counselor
at the University of South Carolina, is the faculty thesis advisor for this study. If you have any
questions about this study, you may contact us:
Erika Jackson, BS
Phone: (541) 729-9955
Email: erika.jackson@uscmed.sc.edu
Janice G. Edwards, MS, CGC
Phone: (803) 545-5706
Email: janice.edwards@uscmed.sc.edu
For questions about your rights as a participant, you may contact the Office of Research
Compliance at the University of South Carolina at (803) 777-7095.
By accessing the online survey by clicking the “Next” button below, you are indicating your
consent to participate in this study.
Thank you for sharing your insight.
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